|
|
|
1-10 employees
View all
|
|
Biotechnology
|
|
5810 West 78th Street, Suite 222, Minneapolis, MN 55439, US
|
|
Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors.
Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all tumor tissue is removed. We are first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors.
Our approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic-assisted surgical procedures.
|
Vergent Bioscience Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Vergent Bioscience email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Vergent Bioscience customer service number in your country click here to find.
John Santini is the CEO of Vergent Bioscience. To contact John Santini email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.